Guidant CRT-D Non-Ischemic Label Expansion Endorsed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Guidant cardiac resynchronization therapy defibrillators reduce heart failure mortality and symptoms for both ischemic and non-ischemic patients but may not prevent hospitalizations, according to FDA's Circulatory System Devices Panel
You may also be interested in...
Boston Scientific Expects MADIT-CRT Results To Energize CRM Sales
Boston Scientific is preparing a major sales and marketing effort to support an expanded indication for its cardiac resynchronization therapy devices based on the results of the MADIT-CRT trial
Boston Scientific Expects MADIT-CRT Results To Energize CRM Sales
Boston Scientific is preparing a major sales and marketing effort to support an expanded indication for its cardiac resynchronization therapy devices based on the results of the MADIT-CRT trial
CMS Welcomes SCD-HeFT Data, Awaits COMPANION Study For ICD Review
CMS plans to integrate Guidant's COMPANION study findings with recently released data from the SCD-HeFT trial to make a decision on whether to redefine the patient population eligible for ICD coverage